EMEA-002166-PIP01-17-M08 - paediatric investigation plan

lasmiditan

Key facts

• Invented name:
  Reyvow
• Active substance:
  lasmiditan
• Therapeutic area:
  Nervous system disorders
• Decision number:
  P/0342/2024
• PIP number:
  EMEA-002166-PIP01-17-M08
• Pharmaceutical form(s):
  • Tablet
  • Orodispersible tablet
• Condition(s) / indication(s):
  Treatment of migraine
• Route(s) of administration:
  Oral use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  13/09/2024
• Compliance check done:
  No

Decision

P/0342/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for lasmiditan (Rayvow), (EMEA-002166-PIP01-17-M08)

Adopted Reference Number: EMA/414754/2024